CICC International: Maintains Buy rating on Kangfang Bio (09926.HK) with a target price of 183 Hong Kong dollars.

According to the Wisdom Finance APP, CICC released a research report stating that it maintains a "buy" rating on Kangfang Biotech (09926.HK) with a target price of HK$183. As of now, no approved drug has achieved a statistically significant OS benefit in this indication. The bank believes that achieving an HR of less than 0.8 and clearly separated curves with Evorelsti is indeed not easy. Whether HARMONi is approved or not, the latest data once again demonstrates the potential of Evorelsi to become the next generation I/O cornerstone product. The bank maintains its forecast of overseas peak sales of $16.5 billion for Evorelsi after PoS adjustment.